Clinical trialsCompany release
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
Adagene Inc. (ADAG) · Tue 17 Nov 2026
The investigator-initiated study will enrol up to 36 patients with advanced microsatellite stable metastatic colorectal cancer, testing the combination first alone and then alongside chemotherapy.
Adagene and City of Hope announced on 17 November 2026 that they have started an investigator-initiated Phase 1 trial combining ivonescimab with muzastotug (ADG126) in advanced microsatellite stable metastatic colorectal cancer.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Adagene Inc. ↗
Article written by VigiEye from the official source (Adagene Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026